Novartis Doubles Up In Optogenetics With Arctos Buy
Complements Acquisition Of Vedere Last Year
The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.
You may also be interested in...
Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.